AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03453944 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VentFree prototype (VF03-K) sham stimulation
Description: Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
Study NCT04900194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based sexual counseling
Description: Mindfulness-based sexual counseling was planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session lasted 30-40 minutes on average. The sessions were carried out individually by determining the appropriate days of pregnant women in the pregnancy class.In the study, the meditation techniques of the Mindfulness Therapy constituted the backbone/framework of the psychoeducation program. Body and breath, body scanning, mindfulness movement and three-minute respiration techniques were practiced during the psychoeducation program, practically every session in accordance with the researchers' directives.
Study NCT01411696 — intervention group
Intervention type: DRUG
Intervention: dexamethasone intravitreal implant 0.7 mg
Description: Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
Study NCT02233309 — intervention group
Intervention type: OTHER
Intervention: Monitoring of pressures during caudal anesthesia
Description: The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
Study NCT02328755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-IFN-α
Study NCT02328755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplant (HCT)
Study NCT02328755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
Study NCT02328755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
Study NCT03125681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
Study NCT04483011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RiaGev
Description: Dietary supplementation
Study NCT04483011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RiaGev
Description: Dietary supplementation
Study NCT03125681 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
Study NCT03481660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection
Study NCT03481660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study NCT02808195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced therapy
Study NCT02808195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinect-based constraint-induced therapy
Study NCT03115853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg daily for 2 weeks
Study NCT03115853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet for Aliskerin
Study NCT03115853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Description: HCTZ 25mg every day for 18 weeks
Study NCT03864211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Description: Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.
Study NCT03864211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation.
Study NCT03864211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation.
Study NCT03115853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg for 4 weeks
Study NCT02801279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional bilateral arm training
Description: The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
Study NCT02801279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinect-based bilateral arm training
Description: The conventional bilateral arm training focuses activities that required the use of both hands.
Study NCT02944357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02944357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02944357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo cystectomy
Study NCT02944357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Cell-Derived Vaccine Therapy
Description: Given AGS-003-BLD ID
Study NCT02241876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Study NCT03920293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
Study NCT03920293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
Study NCT00651495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient decision aids for chronic conditions
Description: Videos providing comprehensive information about chronic disease management
Study NCT00651495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient decision aids for chronic conditions
Description: Videos providing comprehensive information about chronic disease management
Study NCT05499208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving side position with patient turning and movement system
Description: To provide effective breastfeeding by placing the mother in position.
Study NCT00799487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCERTA (methylphenidate HCl) or placebo
Description: Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
Study NCT00799487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCERTA (methylphenidate HCl) or placebo
Description: Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
Study NCT01052051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 2000 IU/daily
Study NCT03606707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: intra-articular steroid injection for atlantoaxial joint
Study NCT00954798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
Study NCT00954798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
Study NCT01052051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 2000 IU/daily
Study NCT01052051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Calcium carbonate 1500mg / daily
Study NCT00954798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21
Study NCT03742999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy program
Description: this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
Study NCT03742999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Link Upper Limb Exerciser
Description: The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
Study NCT03742999 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: physical therapy program and ELink Upper Limb Exerciser
Description: physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
Study NCT01620164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychophysical measurements of 3D perception
Description: 3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
Study NCT02760771 — intervention group
Intervention type: OTHER
Intervention: with BAV
Description: balloon dilation of the aortic valve prior to implantation of the THV
Study NCT02760771 — intervention group
Intervention type: OTHER
Intervention: without BAV
Description: no balloon dilation of the aortic valve prior to implantation of the THV
Study NCT01069861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildanefil
Description: Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
Study NCT00504504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
Study NCT00504504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study NCT00504504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study NCT00504504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study NCT00504504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC)
Description: 375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study NCT01691885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: 100mcg Once daily
Study NCT01052051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Calcium carbonate 1500mg / daily
Study NCT05548166 — intervention group
Intervention type: OTHER
Intervention: Interview and scale development
Description: Interview and scale development
Study NCT01691885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Furoate
Description: 100mcg Once daily
Study NCT01691885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: 25mcg Once daily
Study NCT03389867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract
Study NCT01691885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vilanterol
Description: 25mcg Once daily
Study NCT03581539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverses Abdominis Plane (TAP) block
Description: TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
Study NCT03581539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum (QL) block
Description: QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
Study NCT03581539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon Infiltration using Exparel
Description: SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
Study NCT02568098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
Description: Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
Study NCT00766272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
Study NCT02070081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery or sleeve surgery
Study NCT00846911 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
Study NCT02568098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ and DHA-PQP and PQ
Description: Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
Study NCT03867929 — intervention group
Intervention type: OTHER
Intervention: 25-Hydroxy vitamin D
Description: 27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
Study NCT01711944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem-Solving Skills Training
Description: 8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
Study NCT04481750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension
Study NCT02568098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PQP
Description: Regimen 6: DHA-PQP
Study NCT00037817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: assigned dose level on day 4 and day 10 of each 34 day cycle
Study NCT01711944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Skills Training
Description: 8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
Study NCT01628718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Disclosure (AD)
Description: Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
Study NCT00037817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: assigned dose level on day 4 and day 10 of each 34 day cycle
Study NCT00037817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400mg PO BID on days 4 through 34 of each cycle
Study NCT02976480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
Study NCT02976480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No irrigation
Description: A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
Study NCT03829943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Blood will be drawn for Vitamin D level
Study NCT01944566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial transplant
Description: Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
Study NCT04621214 — intervention group
Intervention type: DEVICE
Intervention: Audio-Visual Triage System (AVT)
Description: Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
Study NCT01882010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days
Study NCT01882010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline solution daily subcutaneous injection 56 days